Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pfizer (PFE)

Pfizer CFO Dave Denton to step down August 15; Cecile Guegan named interim CFO

Neutral Impact 4 of 5 leadership Written later

Pfizer said Chief Financial Officer Dave Denton will leave the company on August 15, 2026 to take a consumer goods role outside the pharmaceutical industry. The company said the departure is not related to its financial or operating results. Cecile Guegan, a Pfizer finance executive since 2005, will serve as interim CFO from August 16 while Pfizer searches for a permanent successor.

Key points

  • Dave Denton notified Pfizer on June 16, 2026 that he will step down as CFO effective August 15, 2026
  • Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, becomes Interim CFO effective August 16, 2026
  • Pfizer is conducting a comprehensive internal and external search for a permanent successor
  • Chairman and CEO Albert Bourla credited Denton with leading transactions including Seagen, Biohaven and Metsera

The filing

CompanyPfizer (PFE)
Form8-K, current report
Filed with the SECJun 18, 2026, 7:07 AM ET
Accession number0000078003-26-000085

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.